NewAmsterdam Pharma Company NV

NASDAQ:NAMS

18.22

+0.65 (+3.70%)

4:36:54 PM EDT: $18.50 +0.28 (+1.54%)

Market Cap (Intraday)	1.70B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$1.87 Million
Adjusted EPS	-$0.50

See more estimates

10-Day MA	$16.93
50-Day MA	$16.49
200-Day MA	$18.84

See more pivots

NewAmsterdam Pharma Company NV Stock, NASDAQ:NAMS

Gooimeer 2-35, 601 Union Street, Naarden, Noord-Holland 1411 DC

Netherlands

Phone: +31.35.206.29.71

Number of Employees: 29

http://www.newamsterdampharma.com

Description

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.